Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04316624CT.gov A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy | — | Completed | — | — | — |
NCT03097770CT.gov Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | — | Completed | — | — | — |
NCT02846584CT.gov a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | — | Unknown | — | — | — |
NCT02737085CT.gov the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| C-Car066 (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB · 64 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for C-Car066
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P2 | BB · 67 |
| Hematopoietic And Lymphoid System Neoplasm | — | P1/2 | CCC · 52 |
| Lymphoma | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. C-Car066 in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/c-car066-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →